JAK1 and prostate carcinoma: Since epigenetic silencing of JAK1 was reported in prostate cancer cell lines [17, 45], we next analyzed the extent of methylation of JAK1 in patient-derived samples of the TCGA cohort [39], and correlated this methylation with JAK1 expression levels (Figure 3A).